lipid nanoparticle-encapsulated ebv mrna vaccine mrna-1189
Generic: Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189
lipid nanoparticle-encapsulated ebv mrna vaccine mrna-1189: 1 clinical trial tracked.
lipid nanoparticle-encapsulated ebv mrna vaccine mrna-1189 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about lipid nanoparticle-encapsulated ebv mrna vaccine mrna-1189, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase 1, Randomized, Open-label Study to Evaluate Safety, Reactogenicity, and Immunogenicity of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, Following Intradermal and Intramuscular Delivery in Healthy Adults 18 to 30 Years of Age
Primary endpoint: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
InterventionalRandomizedopen120 targetStarted 2026-03Completion 2027-052 sites · AustraliaModernaTX, Inc.